Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
Suzanne M. Garland, Punnee Pitisuttithum, Hys Ngan, et al.
The Journal of Infectious Diseases (2018) Vol. 218, Iss. 1, pp. 95-108
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
Supitcha Kamolratanakul, Punnee Pitisuttithum
Vaccines (2021) Vol. 9, Iss. 12, pp. 1413-1413
Open Access | Times Cited: 161
Opportunities and challenges for human papillomavirus vaccination in China
Chao Zhao, Yun Zhao, Jingran Li, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis
Courtney A. Gidengil, Matthew Bidwell Goetz, Sydne J Newberry, et al.
Vaccine (2021) Vol. 39, Iss. 28, pp. 3696-3716
Open Access | Times Cited: 50
<p>Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus</p>
Zheng Quan Toh, Jennie Kosasih, Fiona M. Russell, et al.
Infection and Drug Resistance (2019) Vol. Volume 12, pp. 1951-1967
Open Access | Times Cited: 50
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study
Elmar A. Joura, Àngels Ulied, Corinne Vandermeulen, et al.
Vaccine (2021) Vol. 39, Iss. 20, pp. 2800-2809
Open Access | Times Cited: 33
The impact of alternate HPV vaccination and cervical screening strategies in Japan: a cost-effectiveness analysis
Matthew Palmer, Eiko Saito, Kota Katanoda, et al.
The Lancet Regional Health - Western Pacific (2024) Vol. 44, pp. 101018-101018
Open Access | Times Cited: 5
Outcomes and associated factors of cervical human papillomavirus infection among 608 women in Shenzhen, China, 2018–2023
Zhenghan Lv, Xuesen He, Zhiju Li, et al.
Frontiers in Public Health (2025) Vol. 12
Open Access
Meta-Analysis of Clinical Trial on the Comparative Efficacy and Safety Profiles of Immunotherapeutic Strategies in Cervical Cancer
V Navya, Ravindra Kumar
Critical Reviews in Oncology/Hematology (2025), pp. 104673-104673
Closed Access
Recommendations and Guidance for Human Papillomavirus (HPV) Vaccination for Adults in Taiwan
Kuan‐Yin Lin, I-Fan Lin, Ping-Feng Wu, et al.
Journal of Microbiology Immunology and Infection (2025)
Open Access
Chinese mothers’ intention to vaccinate daughters against human papillomavirus (HPV), and their vaccine preferences: a study in Fujian Province
Yulan Lin, Zhitai Su, Fulian Chen, et al.
Human Vaccines & Immunotherapeutics (2020) Vol. 17, Iss. 1, pp. 304-315
Open Access | Times Cited: 32
A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
Tsetsegsaikhan Batmunkh, Marguerite T. Dalmau, Margad-Erdene Munkhsaikhan, et al.
Vaccine (2020) Vol. 38, Iss. 27, pp. 4316-4324
Open Access | Times Cited: 27
Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis
Jianming Guo, Shuyan Guo, Siping Dong
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 9
HPV prevalence and genotype distribution among women in eastern China during the Covid-19 pandemic
Yongmei Ma, Xiyan Xia, Wen Zheng, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 9
The prevalence and genotype distribution of high-risk human papillomaviruses among women in Xianning, China
Bin Qiu, Na Jiang, Jinpeng Jiang, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Distribution of Human Papillomavirus (HPV) Genotypes in HIV-Negative and HIV-Positive Women with Cervical Intraepithelial Lesions in the Eastern Cape Province, South Africa
Ongeziwe Taku, Zizipho Z. A. Mbulawa, Keletso Phohlo, et al.
Viruses (2021) Vol. 13, Iss. 2, pp. 280-280
Open Access | Times Cited: 22
Epidemiological study of human papillomavirus infection in 105,679 women in Wuhan, China
Weina Guo, Hu Zhao, Jun Yan, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Associations between population based voting trends during the 2016 US presidential election and adolescent vaccination rates
Manika Suryadevara, Cynthia A. Bonville, Donald A. Cibula, et al.
Vaccine (2019) Vol. 37, Iss. 9, pp. 1160-1167
Closed Access | Times Cited: 21
Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study
Huakun Lv, Shenyu Wang, Zhenzhen Liang, et al.
Vaccine (2022) Vol. 40, Iss. 23, pp. 3263-3271
Closed Access | Times Cited: 10
A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26
Miao Yu, Xin Chi, Shiwen Huang, et al.
Vaccine (2022) Vol. 40, Iss. 42, pp. 6141-6152
Open Access | Times Cited: 9
Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
Tak Hong Cheung, Sally Shuk Yee Cheng, Danny Hsu, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 5
Post-marketing study design to evaluate the effectiveness of the 9-valent and 4-valent HPV vaccines on serious HPV-related cervical disease in China
Yang Yu, Liang Zhang, Susanne Hartwig, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
Tak Hong Cheung, Sally Shuk Yee Cheng, Danny Hsu, et al.
Cost Effectiveness and Resource Allocation (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 8
Risk factors associated with severe recurrent respiratory papillomatosis
Muddaseer Khan, Tesuven K. Naidu
Southern African Journal of Infectious Diseases (2019) Vol. 34, Iss. 1
Open Access | Times Cited: 6
Affective and Cognitive Attitudes on Cervical Health Behaviors Among Asian American Women
Jongwon Lee, Mauricio Carvallo, Eunice Lee, et al.
Family & Community Health (2019) Vol. 42, Iss. 2, pp. 123-132
Closed Access | Times Cited: 5
PAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART 2. HPV-ASSOCIATED CANCERS IN RUSSIA. PREVENTIVE HPV VACCINES
Г. М. Волгарева
Russian Journal of Biotherapy (2020) Vol. 19, Iss. 2, pp. 31-38
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top